Prime time: First therapeutic clinical trial of C'Dots underway

C’Dots, silica-encased nanoparticles developed in the lab of engineering professor Ulrich Wiesner, have just begun their first therapeutic human clinical trial. They’re being further developed by Elucida Oncology Inc., a company co-founded by Wiesner.

Related Keywords

New Jersey ,United States ,Monmouth Junction ,Bard Hall ,Kai Ma ,Spencert Olin ,Uli Wiesner ,Melik Turker ,Ulrich Wiesner ,Paul Rudick ,Tom Gardinier ,Elucida Cdcs ,Geno Germano ,Fei Wu ,Heaney Cornell University Dots ,Tumor Group Expansion Cohort ,Elucida Oncology Inc ,Cornell Prime Dots ,Elucida Oncology ,New Jersey Based ,Cornell University ,Cornell Dots ,Escalation Safety Study ,Group Expansion Cohort ,